DYRK1A suppression attenuates HIF-1α accumulation and enhances the anti-liver cancer effects of regorafenib and sorafenib under hypoxic conditions

Hypoxia promotes drug resistance and induces the expression of hypoxia inducible factor (HIF)-1α in liver cancer cells. However, to date, no selective HIF-1α inhibitor has been clinically approved. The aim of this study is to investigate a drug-targetable molecule that can regulate HIF-1α under hypo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chong, Wu, Lin-Wen, Li, Zhi-Di, Zhang, Man-Man, Wu, Jie, Du, Fei-Hua, Zeng, Ling-Hui, Li, Yang-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923653/
https://www.ncbi.nlm.nih.gov/pubmed/35244188
http://dx.doi.org/10.3892/ijo.2022.5335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923653/
https://www.ncbi.nlm.nih.gov/pubmed/35244188
http://dx.doi.org/10.3892/ijo.2022.5335

Ejemplares similares